CHAD Therapeutics Plans to Begin Trading on the OTC Bulletin Board
08 8월 2008 - 5:15AM
Business Wire
CHAD Therapeutics, Inc. (AMEX:CTU) announced today that it plans to
withdraw its common stock from the American Stock Exchange
effective on August 29, 2008 because the Company no longer meets
certain quantitative listing requirements, and plans to begin
trading on the OTC Bulletin Board system effective on September 2,
2008, the next trading day, under the new symbol CTUI. On July 29,
2008, CHAD announced that its Dormio Tech division received 510(K)
clearance from the FDA to market the Company's proprietary
FloCHANNEL� Diagnostic System, Dormio's first product for the large
and rapidly growing sleep disorder market. CHAD currently expects
to begin shipping this new device and associated disposables by
September. About CHAD Therapeutics CHAD Therapeutics, Inc. develops
and markets innovative products for the sleep disorder market. For
more information, visit www.dormiotech.com. Safe Harbor Statements
under the Private Securities Litigation Reform Act of 1995. The
foregoing statements regarding prospects for future earnings and
revenues, future sales trends and the introduction of products
under development are forward-looking statements that involve
certain risks and uncertainties. A number of important factors
could cause actual results to differ materially from those
contemplated by such forward-looking statements. These include the
introduction of new products with perceived competitive advantages
over the Company's products, changes or proposed changes in health
care reimbursement which affect home care providers, and DORMIO's
ability to anticipate and respond to technological and economic
changes in the sleep market. Moreover, the success of the Company's
products and products under development will depend on their
efficacy, reliability and the health care community's perception of
the products' capabilities and benefits, the degree of acceptance
the products achieve among sleep labs and patients, and, with
respect to products under development, obtaining timely regulatory
approval. Additional factors that could cause actual results to
differ materially from those contemplated in this press release can
be found in the Company's annual and quarterly reports filed with
the Securities and Exchange Commission under the caption "Outlook:
Issues and Risks."
Chad Therapeutics (AMEX:CTU)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Chad Therapeutics (AMEX:CTU)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
Chad Therapeutics, (아메리카 증권거래소)의 실시간 뉴스: 최근 기사 0
More CHAD Therapeutics, Inc. News Articles